Focusing on value investment opportunities in the Japanese market, building a "cross-border industrial empowerment platform", achieving through "capital + operation" dual-wheel drive:
Our parent company was founded in Shanghai's North Bund in 2014, positioned as an early-stage venture capital and expansion-stage growth investment firm. It is a comprehensive financial investment company focused on venture capital, with M&A transactions as the strategic direction, and primary and secondary market linkage.
Ryoshi Investment is a next-generation investment platform centered on "technological innovation × social issue resolution." Based on our Chinese parent company's deep accumulation in healthcare and education sectors, we established our presence in Tokyo in 2025, committed to addressing Japan's unique challenges of declining birthrate and aging society and digital transformation needs, capturing Asian market growth opportunities through China-Japan synergy effects.
Learn More →
Leveraging China's Hongyi Group network, providing one-stop support for China-Japan technology transfer, qualification certification, and market expansion
Combining portfolio company technologies to create new business models
Possessing a leading domestic mRNA sequence design technology platform targeting diseases, with the latest groundbreaking rabies vaccine successfully developed and entering clinical and application stages. The first company in China to successfully complete COVID-19 vaccine animal experiments. Leading domestic mRNA vaccine R&D enterprise, with rabies vaccine in clinical stage and COVID-19 vaccine animal trials pioneering success.
One of China's first professional national high-tech enterprises specializing in tumor precision medicine molecular diagnostic reagent R&D and production. Independently developing and producing over 20 types of tumor precision medicine molecular diagnostic reagents, one of the most comprehensive companies in the domestic industry.
A well-known preclinical CRO professional institution in East China, specializing in non-clinical drug toxicology research and safety evaluation technical services, one of the six domestic institutions with the most comprehensive non-clinical drug safety evaluation test projects.
A high-tech enterprise specializing in gene diagnostic product R&D, production, and sales, one of the leading domestic molecular diagnostic reagent manufacturers. The first company in China to obtain COVID-19 testing reagent medical license.
A tumor liquid biopsy service provider with LiquidBiopsy technology and MDA test tumor liquid biopsy technology, focusing on CTC capture and detection technology research, whose products and services can assist doctors in making diagnosis and treatment recommendations for patients.
Specializing in adolescent scoliosis correction, poor posture correction, spinal sub-health pain management, etc., adopting multi-dimensional solutions including diagnosis, assessment, exercise rehabilitation, manual correction, and physical therapy, committed to solving national spinal health problems, currently operating eight clinics in Shanghai, Hangzhou, Shenzhen, Hefei, Ningbo, and other cities.
Three major cooperation paths designed for Japanese market characteristics:
Assisting Japanese advanced technology commercialization in Chinese market
Providing specialized PMDA certification services for Chinese medical devices
Building China-Japan cross-border M&A bridges
Establishing strategic partnerships with industry-leading companies to jointly promote innovative development
